Altimmune, Inc. (ALT): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Altimmune (ALT) will present data on pemvidutide at the AASLD meeting, showing positive results from its IMPACT Phase 2b study in MASH, including reductions in fibrosis markers and liver fat. The company also reported mild adverse events and initiated a Phase 3 trial for MASH and completed enrollment for a Phase 2 trial in alcohol-associated liver disease.

Altimmune (ALT) will present new data on pemvidutide at AASLD 2026, including 48-week Phase 2b results and preclinical findings. The data shows reductions in fibrosis markers, improved GI tolerability, and reduced alcohol intake in a hamster model. The update reinforces earlier Phase 2b signals and advances the drug into Phase 3 trials.

Altimmune (ALT) reported Q2 results, highlighting progress in three liver disease trials. The company launched a global Phase 3 trial for MASH, reported positive Phase 2 data for alcohol use disorder, and completed enrollment for a Phase 2 trial in alcohol-associated liver disease. Altimmune has no approved products and reported a net loss of $22.8 million, with cash reserves of $519 million as of June 30.

Altimmune has begun a Phase 3 trial for pemvidutide, a dual-hormone drug targeting metabolic dysfunction-associated steatohepatitis (MASH). The drug uniquely balances glucagon and GLP-1 receptor activation, aiming to address liver fat and fibrosis. The trial's success could validate its differentiation in a crowded market. Altimmune's valuation is highly dependent on the outcome, with a price-to-sales ratio of 72.5x.

Lululemon (LULU), Lucid (LCID), and Altimmune (ALT) hit 52-week lows due to leadership uncertainty, financial strain, and strategic concerns. LULU dropped 13% after naming a new CEO, LCID fell 9% amid funding and production cost worries, and ALT declined 16% following a stock offering. Uber owns 11.52% of LCID.

Altimmune (Nasdaq: ALT) reported Q2 2026 results and a business update. The company initiated the global PERFORMA Phase 3 MASH trial, reported positive topline RECLAIM Phase 2 AUD data, and completed enrollment in the RESTORE Phase 2 ALD trial. Cash, cash equivalents and investments were $519 million as of June 30, 2026. R&D was $18.7 million and net loss $22.8 million.